Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Seeking Alpha5/7/2026Neutral
SGHT
Sight Sciences IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$291.09M
P/E Ratio
—
EPS
$-0.68
Beta
2.38
52W High
$9.24
52W Low
$3.11
50-Day MA
$4.92
200-Day MA
$5.38
Dividend Yield
—
Profit Margin
-46.80%
Forward P/E
—
PEG Ratio
—
About Sight Sciences Inc
Sight Sciences Inc. (SGHT) is a leading medical technology company dedicated to innovating the treatment of ocular diseases, particularly through advanced solutions for glaucoma management. With a strong focus on both surgical and non-surgical methods, the company boasts a diverse product portfolio complemented by a comprehensive intellectual property strategy. As the demand for minimally invasive ophthalmic therapies continues to grow, Sight Sciences is strategically positioned to capture market share and enhance patient outcomes. Its commitment to advancing eye care technology and optimizing its distribution network presents a valuable investment opportunity within the rapidly evolving healthcare landscape.
Fundamentals
| Revenue (TTM) | $79.55M |
| Gross Profit (TTM) | $68.55M |
| EBITDA | $-27.01M |
| Operating Margin | -35.60% |
| Return on Equity | -56.60% |
| Return on Assets | -14.30% |
| Revenue/Share (TTM) | $1.51 |
| Book Value | $1.00 |
| Price-to-Book | 5.49 |
| Price-to-Sales (TTM) | 3.66 |
| EV/Revenue | 3.178 |
| EV/EBITDA | -4.25 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.50% |
| Shares Outstanding | $54.41M |
| Float | $35.20M |
| % Insiders | 19.98% |
| % Institutions | 53.70% |
Historical Volatility
HV 10-Day
49.88%
HV 20-Day
50.33%
HV 30-Day
56.31%
HV 60-Day
74.55%
HV Rank
19.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($8.54 target)
1
Strong Buy3
Buy2
HoldLatest News
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2026 and raised its revenue guidance for full year 2026.
GlobeNewsWire5/6/2026Neutral
Sight Sciences to Present at Two Upcoming Investor Conferences
MENLO PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at two upcoming conferences.
GlobeNewsWire4/29/2026Neutral
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2026, after the market close on Wednesday, May 6, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GlobeNewsWire4/21/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026